Last reviewed · How we verify
Sex-mismatched red blood cell transfusions
Sex-mismatched red blood cell transfusions is a Biologic drug developed by Michelle Zeller. It is currently FDA-approved.
At a glance
| Generic name | Sex-mismatched red blood cell transfusions |
|---|---|
| Sponsor | Michelle Zeller |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Effects of Donor-recipient Sex-matched Blood Transfusion on Patient Outcomes (PHASE4)
- Pilot Study of Sex-matched vs. Sex-mismatched Red Blood Cell Transfusion (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sex-mismatched red blood cell transfusions CI brief — competitive landscape report
- Sex-mismatched red blood cell transfusions updates RSS · CI watch RSS
- Michelle Zeller portfolio CI
Frequently asked questions about Sex-mismatched red blood cell transfusions
What is Sex-mismatched red blood cell transfusions?
Sex-mismatched red blood cell transfusions is a Biologic drug developed by Michelle Zeller.
Who makes Sex-mismatched red blood cell transfusions?
Sex-mismatched red blood cell transfusions is developed and marketed by Michelle Zeller (see full Michelle Zeller pipeline at /company/michelle-zeller).
What development phase is Sex-mismatched red blood cell transfusions in?
Sex-mismatched red blood cell transfusions is FDA-approved (marketed).